论文部分内容阅读
目的 探讨环孢霉素A(CsA)联合他莫昔芬 (TAM)逆转大肠癌多药耐药的临床疗效。方法 用免疫组织化学技术对大肠癌的P -蛋白表达进行检测 ,筛选阳性病例同时进行骨髓微小转移测定 ,选择二者皆为阳性患者作为研究对象 ,并随机分为两组 ,比较CsA联合TAM加化疗组与单纯化疗组疗效。结果 在大肠癌中P -蛋白表达阳性率为 6 6 6 % (5 6 /84 ) ,在p糖蛋白 (P -gp)阳性病例中 ,骨髓微小转移 (BMM)阳性率为 5 7 1% (32 /5 6 )。CsA联合TAM对逆转大肠癌多药耐药有一定作用 ,加逆转剂组疗效高于不加逆转剂组 (P <0 .0 5 )。结论 CsA联合TAM对逆转大肠癌多药耐药的临床应用安全 ,且有一定疗效
Objective To investigate the clinical efficacy of cyclosporin A (CsA) combined with tamoxifen (TAM) in reversing multidrug resistance of colorectal cancer. Methods Immunohistochemical technique was used to detect the expression of P - protein in colorectal cancer. The positive cases were screened for micrometastasis at the same time. The positive patients were selected as research subjects and divided into two groups at random. The levels of CsA combined with TAM plus Chemotherapy group and chemotherapy alone group. Results The positive rate of P - protein in colorectal cancer was 66.6% (56/84). The positive rate of bone marrow micrometastasis (BMM) was 57.1% (P <0.05) in the cases with positive P - glycoprotein 32/5 6). CsA combined with TAM can reverse the multidrug resistance of colorectal cancer to a certain extent, and the effect of adding reversal agent is better than that without reversal agent (P <0.05). Conclusion The clinical application of CsA combined with TAM in reversing the multidrug resistance of colorectal cancer is safe and has a certain effect